Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs, AEI Rep Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Because catastrophic drug costs will be picked up by the government under Part D, private Medicare drug plans may have little incentive to manage use of high-cost biotech products, American Enterprise Institute Resident Fellow Gottlieb says. However, high government spending eventually could lead to political backlash.
You may also be interested in...
Drug Safety, Part D Reimbursement Elevate Biotech Venture Capital Risk, Fund Manager Says
Increased risks could result in lower valuations for biotech start-ups, Vector Fund Management Managing Director Phillips tells BIO annual meeting, which "makes it very, very hard for entrepreneurs to raise money." VC focus is shifting to less-risky, later-stage development, he says.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability